{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:17:03Z","timestamp":1793261823570,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001448","name":"Alpha-1 Foundation","doi-asserted-by":"publisher","award":["553700"],"award-info":[{"award-number":["553700"]}],"id":[{"id":"10.13039\/100001448","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010890","name":"Central People's Government of the People's Republic of China Scholarship Programme","doi-asserted-by":"publisher","award":["201707040053"],"award-info":[{"award-number":["201707040053"]}],"id":[{"id":"10.13039\/501100010890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jconrel.2025.113643","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T13:21:52Z","timestamp":1742304112000},"page":"113643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Impact of administration route and PEGylation on alpha-1 antitrypsin augmentation therapy"],"prefix":"10.1016","volume":"382","author":[{"given":"Xiao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Ucakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Vanvarenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Marbaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Vanbever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113643_bb0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/TCRM.S51474","article-title":"Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes","volume":"11","author":"Chotirmall","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"issue":"Suppl. 4","key":"10.1016\/j.jconrel.2025.113643_bb0010","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1513\/AnnalsATS.201507-468KV","article-title":"Well-known and less well-known functions of Alpha-1 antitrypsin. Its role in chronic obstructive pulmonary disease and other disease developments","volume":"13","author":"Janciauskiene","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.jconrel.2025.113643_bb0015","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMra1910234","article-title":"Alpha1-antitrypsin deficiency","volume":"382","author":"Strnad","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113643_bb0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1753465810373911","article-title":"Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies","volume":"4","author":"Tonelli","year":"2010","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.jconrel.2025.113643_bb0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00673-2019","article-title":"Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD","volume":"54","author":"Stolk","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2025.113643_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.rmed.2003.09.001","article-title":"COPD exacerbations: the importance of a standard definition","volume":"98","author":"Pauwels","year":"2004","journal-title":"Respir. Med."},{"key":"10.1016\/j.jconrel.2025.113643_bb0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1183\/09031936.93.04010040","article-title":"Proteolytic inactivation of alpha 1-proteinase inhibitor in infected bronchial secretions from patients with cystic fibrosis","volume":"4","author":"Suter","year":"1991","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2025.113643_bb0040","doi-asserted-by":"crossref","first-page":"27258","DOI":"10.1016\/S0021-9258(19)61505-X","article-title":"Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity","volume":"275","author":"Taggart","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.113643_bb0045","first-page":"L1002","article-title":"Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules","volume":"286","author":"Lombry","year":"2004","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2025.113643_bb0050","doi-asserted-by":"crossref","first-page":"2101633","DOI":"10.1002\/adfm.202101633","article-title":"Protein engineering strategies for improved pharmacokinetics","volume":"31","author":"Rondon","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.113643_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120107","article-title":"PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages","volume":"593","author":"Mahri","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113643_bb0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.procbio.2016.09.029","article-title":"Effect of protein immunogenicity and PEG size and branching on the anti-PEG immune response to PEGylated proteins","volume":"52","author":"Wan Xue","year":"2017","journal-title":"Process Biochem."},{"key":"10.1016\/j.jconrel.2025.113643_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cocis.2017.08.001","article-title":"PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals","volume":"31","author":"Guichard","year":"2017","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2025.113643_bb0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2014.05.021","article-title":"PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract","volume":"187","author":"Koussoroplis","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113643_bb0075","doi-asserted-by":"crossref","first-page":"2000146","DOI":"10.1002\/adtp.202000146","article-title":"PEGylation of recombinant human deoxyribonuclease I provides a long-acting version of the mucolytic for patients with cystic fibrosis","volume":"4","author":"Guichard","year":"2021","journal-title":"Adv. Therapeut."},{"key":"10.1016\/j.jconrel.2025.113643_bb0080","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1165\/rcmb.4866","article-title":"Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor","volume":"27","author":"Cantin","year":"2002","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2025.113643_bb0085","doi-asserted-by":"crossref","first-page":"121355","DOI":"10.1016\/j.ijpharm.2021.121355","article-title":"Production and characterization of mono-PEGylated alpha-1 antitrypsin for augmentation therapy","volume":"612","author":"Liu","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113643_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4392","article-title":"Impact of the PEG length and PEGylation site on the structural, thermodynamic, thermal, and proteolytic stability of mono-PEGylated alpha-1 antitrypsin","volume":"31","author":"Liu","year":"2022","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2025.113643_bb0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2017.12.009","article-title":"Fate of PEGylated antibody fragments following delivery to the lungs: influence of delivery site, PEG size and lung inflammation","volume":"272","author":"Patil","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113643_bb0100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/CS20140654","article-title":"A short-term mouse model that reproduces the immunopathological features of rhinovirus-induced exacerbation of COPD","volume":"129","author":"Singanayagam","year":"2015","journal-title":"Clin. Sci."},{"key":"10.1016\/j.jconrel.2025.113643_bb0105","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/jps.21152","article-title":"Endotoxin limits in formulations for preclinical research","volume":"97","author":"Malyala","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113643_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106522","article-title":"Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: a technical feasibility study","volume":"189","author":"Mahri","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113643_bb0115","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0003-9861(78)90286-2","article-title":"The inhibition of human leukocyte elastase by basic pancreatic trypsin inhibitor","volume":"190","author":"Lestienne","year":"1978","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jconrel.2025.113643_bb0120","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113643_bb0125","doi-asserted-by":"crossref","first-page":"L931","DOI":"10.1152\/ajplung.00150.2009","article-title":"Elastase- and LPS-exposed mice display altered responses to rhinovirus infection, American journal of physiology","volume":"297","author":"Sajjan","year":"2009","journal-title":"Lung Cell. Mole. Pphysiol."},{"key":"10.1016\/j.jconrel.2025.113643_bb0130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2567.2007.02641.x","article-title":"The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response","volume":"122","author":"Minne","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2025.113643_bb0135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/bc000082g","article-title":"Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C","volume":"12","author":"Bailon","year":"2001","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.113643_bb0140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10719-016-9657-3","article-title":"Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulatory half-life in Sprague-Dawley rats","volume":"33","author":"Chung","year":"2016","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.jconrel.2025.113643_bb0145","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0192623315591171","article-title":"PEGylated biopharmaceuticals: current experience and considerations for nonclinical development","volume":"43","author":"Ivens","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2025.113643_bb0150","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1021\/acs.molpharmaceut.9b00033","article-title":"Cationic Nanoliposomes are efficiently taken up by alveolar macrophages but have little access to dendritic cells and interstitial macrophages in the Normal and CpG-stimulated lungs","volume":"16","author":"Vanbever","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113643_bb0155","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/jps.21635","article-title":"Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability","volume":"98","author":"Gursahani","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113643_bb0160","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2025.113643_bb0165","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0073-2019","article-title":"Alpha(1)-antitrypsin deficiency and chronic respiratory disorders","volume":"29","author":"Cazzola","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jconrel.2025.113643_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063344","article-title":"Mucosal and systemic immune responses to mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice","volume":"8","author":"Todoroff","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2025.113643_bb0175","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0192623320976094","article-title":"BSTP review of 12 case studies discussing the challenges, pathology, immunogenicity, and mechanisms of inhaled biologics","volume":"49","author":"Hall","year":"2021","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2025.113643_bb0180","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/S0021-9258(17)40292-4","article-title":"Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.113643_bb0185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jconrel.2022.09.031","article-title":"Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of PEGylated products","volume":"351","author":"Ibrahim","year":"2022","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925002639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925002639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:56:25Z","timestamp":1777870585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925002639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":37,"alternative-id":["S0168365925002639"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113643","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of administration route and PEGylation on alpha-1 antitrypsin augmentation therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113643"}}